Palvella Therapeutics (PVLA) Net Equity Issued and Repurchased (2013 - 2026)

Palvella Therapeutics (PVLA) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $230.0 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $230.0 million in Q1 2026; TTM through Mar 2026 was $230.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $19.7 million, up 185.02% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $230.0 million, up from $19.7 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for PVLA reached as high as $230.0 million in Q1 2026 and fell as low as $167000.0 in Q2 2022.
• Historically, Net Equity Issued and Repurchased has averaged $51.3 million across 3 years, with a median of $6.5 million in 2022.
• Across the five-year window, Net Equity Issued and Repurchased sank 98.68% in 2022 and soared 11713.77% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $282000.0 in 2022, then surged by 6896.1% to $19.7 million in 2023, then jumped by 1065.8% to $230.0 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $230.0 million in Q1 2026, $19.7 million in Q2 2023, and $282000.0 in Q3 2022.